Serum 25-hydroxyvitamin D levels and C-reactive protein in persons with human immunodeficiency virus infection

AIDS Research and Human Retroviruses

Volumn 29, Issue 3, 2013, Pages 528-534

  Poudel Tandukar, Kalpana ^a   Poudel, Krishna C ^b,c   Jimba, Masamine ^d   Kobayashi, Jun ^e,f   Johnson, C Anderson ^c   Palmer, Paula H ^c  

^a WASEDA UNIVERSITY   (Japan)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c CLAREMONT GRADUATE UNIVERSITY   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^f NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADOLESCENT; ADULT; ARTICLE; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BINDING; RISK ASSESSMENT; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEPAL; SERUM; SEX FACTORS; VITAMIN D; YOUNG ADULT;

EID: 84874490747     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0120     Document Type: Article

References (36)

1. Chi D, Henry J, Kelley J, et al.: The effects of HIV infection on endothelial function. Endothelium 2000;7:223-242.
2. Francisci D, Giannini S, Baldelli F, et al.: HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009;23:589-596.
3. Jahoor F, Gazzard B, Phillips G, et al.: The acute-phase protein response to human immunodeficiency virus infection in human subjects. Am J Physiol 1999;276:E1092-E1098.
4. Zietz C, Hotz B, Sturzl M, et al.: Aortic endothelium in HIV-1 infection: Chronic injury, activation, and increased leukocyte adherence. Am J Pathol 1996;149:1887-1898.
5. Lau B, Sharrett R, Kingsley LA, et al.: C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006;166:64-70.
6. Feldman JG, Goldwasser P, Holman S, et al.: C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. JAIDS 2003;32:210-214.
7. Crutchley RD, Gathe J, Mayberry C, Trieu A, Abughosh S, and Garey KW: Risk factors for vitamin D deficiency in HIVinfected patients in the South Central United States. AIDS Res Hum Retroviruses 2012;28(5):454-459.
8. Cervero M, Agud JL, García-Lacalle C, Alcázar V, Torres R, Jusdado JJ, et al.: Prevalence of vitamin D deficiency and its related risk factor in a Spanish cohort of adult HIV-infected patients: Effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2012;28(9):763-771.
9. Kim JH, Gandhi V, Psevdos G Jr, Espinoza F, Park J, and Sharp V: Evaluation of vitamin D levels among HIV-infected patients in New York City. AIDS Res Hum Retroviruses 2012;28:235-241.
10. Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al.: Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923-1928.
11. Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al.: Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One 2010;5:e8770.
12. Villamor E: A potential role for vitamin D on HIV infection? Nutr Rev 2006;64:226-233.
13. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al.: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: Effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24:1375-1382.
14. Wasserman P and Rubin DS: Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIVinfected men under care. AIDS Patient Care STDS 2010; 24:223-227.
15. Guillot X, Semerano L, Saidenberg-Kermanach N, et al.: Vitamin D and inflammation. Joint Bone Spine 2010;77: 552-557.
16. Wang TJ, Pencina MJ, Booth SL et al.: VitaminDdeficiency and risk of cardiovascular disease. Circulation 2008;29:503-511.
17. Amer M and Qayyum R: Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous national health and nutrition examination survey 2001 to 2006). Am J Cardiol 2012;109: 226-230.
18. Zittermann A: Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006;92:39-48.
19. Patel S, Farragher T, Berry J, et al.: Association between serum vitamin D metabolites levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 2007;56:2143-2149.
20. D' Ambrosio D, Cippitelli M, Cocciolo MG, et al.: Inhibition of IL-12 production by 1, 25-dihyoxyvitamin D3. Involvement of NF-kB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998;101:252-262.
21. Helming L, Bose J, Ehrchen J, et al.: 1Alpha,25-dihydroxyvitamin D3 is a potent suppressor of inferferon gamma-mediated macrophage activation. Blood 2005; 106:4351-4358.
22. Central Bureau of Statistics: Statistical Year Book of Nepal - 2009. Kathmandu: National Centre for AIDS and STD Control, 2007.
23. Ministry of Health and Population: UNGASS Country Progress Report: Nepal, Kathmandu: Ministry of Health and Population, Government of Nepal, 2010.
24. National Centre for AIDS and STD Control: National estimates of HIV infections, Nepal, Kathmandu: National Centre for AIDS and STD Control, 2007.
25. Family Health International, New Era, STD/AIDS Counselling and Training Services: Integrated Biological and Behavioral Surveillance Survey (IBBS) among Male Injecting Drug Users (IDUs) in Kathmandu Valley, Round IV. Kathmandu: Family Health International, 2009.
26. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al.: Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr, 2006;84:18-28.
27. Myers GL, Rifai N, Tracy RP, et al.: CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to clinical and public health practice: Report from the laboratory science discussion group. Circulation 2004;110:e545-e549.
28. Bellia A, Garcovich C, D'Adamo M, et al.: Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med 2011 [Epub ahead of print]; DOI 10.1007/s11739-011- 0559-x.
29. Van den Berghe G, Van Roosbroeck D, Vanhove P, et al.: Bone turnover in prolonged critical illness' effect of vitamin D. J Clin Endocrinol Metab 2003;88:4623-4632.
30. Schleithoff SS, Zittermann A, Tenderich G et al.: Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo controlled trial. Am J Clin Nutr 2006;83: 754-759.
31. Dao CN, Patel P, Overton ET, et al.: Low vitamin D among HIV-infected adults: Prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011;52:396-405.
32. Brown TT and McComsey GA: Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2010;15:425-429.
33. Longenecker CT, Hileman CO, Carman TL, et al.: Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: A randomized placebocontrolled trial. Antivir Ther 2012;17:613-621.
34. Veldman CM, Cantorna MT, and DeLuca HF: Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000;374:334-338.
35. Gysemans CA, Cardozo AK, Callewaert H et al.: 1,25-dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: Implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005;146: 1956-1964.
36. Willheim M, Thien R, Schrattbauer K et al.: Regulatory effects of 1alpha, 25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocyte. J Clin Endocrinol Metab 1999;84:3739-3744.